Private equity firm Warburg Pincus is close to completing an acquisition of specialty pharmacy PANTHERx Rare for a price in excess of $7 billion when debt is included, according to people familiar with the negotiations. The purchase is being pursued in partnership with the Abu Dhabi Investment Authority, the sources said.
Those people cautioned that while a transaction could materialize soon, nothing has been finalized and the timing may still slip. Warburg Pincus manages in excess of $100 billion in assets and maintains multiple healthcare investments, the sources noted, naming START Center for Cancer Research and Simtra BioPharma Solutions among its portfolio holdings.
PANTHERx, headquartered in Pittsburgh, provides specialized medicines and patient support services tailored to rare and orphan diseases. The company is controlled by an investor group that includes private equity firm General Atlantic.
Prior ownership changes for PANTHERx date back to a period in which Centene acquired the company in 2020 and subsequently sold the rare-disease specialty pharmacy in 2022 to a consortium that included General Atlantic, Nautic Partners and The Vistria Group for an undisclosed amount. That divestiture was part of Centene's move to streamline its operations and concentrate on core health insurance activities.
The potential transaction arrives as private equity firms generally seek to accelerate deal activity, driven in part by a backlog of portfolio companies awaiting exits. Buyers in the market have been evaluating opportunities across sectors, and healthcare-related platforms remain an area of focus for several large investors.
Representatives for Warburg Pincus declined to comment, and PANTHERx did not immediately respond to requests for comment.
Context and market implications
From an investor and market-structure perspective, the reported transaction would represent a sizeable takeover within the specialty pharmacy space, reflecting continued private equity interest in healthcare service providers that serve niche patient populations. Given PANTHERx's specialization in rare and orphan disease therapies and patient support services, the acquisition would concentrate ownership of a targeted clinical services platform under a large private equity sponsor working with a sovereign investor partner.
What remains uncertain
According to the reporting, the deal is not yet finalized and timing could shift, leaving room for negotiation outcomes or delays. The price being discussed includes debt, and details such as final terms and timing have not been disclosed publicly.